A Novel Approach to Cancer Therapy using PX-478 as a HIF-1α Inhibitor

被引：64

作者：

Lee, Kyeong ^{[2
]}

Kim, Hwan Mook ^{[1
]}

机构：

[1] Gachon Univ Med & Sci, Coll Pharm, Inchon 406799, South Korea

[2] Dongguk Univ Seoul, Coll Pharm, Seoul 100715, South Korea

来源：

ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 10期

关键词：

HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FACTOR-I; RADIOSENSITIZATION;

D O I：

10.1007/s12272-011-1021-3

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hypoxia-inducible factor-l alpha (HIF-1 alpha) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1 alpha in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1 alpha has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1 alpha inhibitor in clinical stage for the treatment of solid tumors.

引用

下载

页码：1583 / 1585

页数：3

共 50 条

[21] Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α
Koh, Mei Y.
Spivak-Kroizman, Taly
Venturini, Sara
Welsh, Sarah
Williams, Ryan R.
Kirkpatrick, D. Lynn
Powis, Garth
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 90 - 100
[22] PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells
Palayoor, Sanjeewani T.
Mitchell, James B.
Cerna, David
DeGraff, William
John-Aryankalayil, Molykutty
Coleman, C. Norman
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (10) : 2430 - 2437
[23] Inhibition of hypoxia-inducible factor-1α by PX-478 as a potential targeted therapy in ESCC.
Zhu, Yingming
Zang, Yuanwei
Li, Minghuan
Yu, Jinming
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] HIF-1α and RKIP: a computational approach for pancreatic cancer therapy
Srivani, Gowru
Behera, Santosh Kumar
Dariya, Begum
Chalikonda, Gayathri
Alam, Afroz
Nagaraju, Ganji Purnachandra
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 472 (1-2) : 95 - 103
[25] HIF-1α and RKIP: a computational approach for pancreatic cancer therapy
Gowru Srivani
Santosh Kumar Behera
Begum Dariya
Gayathri Chalikonda
Afroz Alam
Ganji Purnachandra Nagaraju
Molecular and Cellular Biochemistry, 2020, 472 : 95 - 103
[26] Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma
Muz, Barbara
Wasden, Katherine
Alhallak, Kinan
Jeske, Amanda
Azab, Feda
Sun, Jennifer
King, Justin
Kohnen, Daniel R.
Vij, Ravi
Azab, Abdel Kareem
BLOOD, 2020, 136
[27] Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines
Parczyk, Jonas
Ruhnau, Jerome
Pelz, Carsten
Schilling, Max
Wu, Hao
Piaskowski, Nicole Nadine
Eickholt, Britta
Kuehn, Hartmut
Danker, Kerstin
Klein, Andreas
BMC CANCER, 2021, 21 (01)
[28] The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects
Schwartz, David L.
Powis, Garth
Thitai-Kumar, Arun
He, Yi
Bankson, James
Williams, Ryan
Lemos, Robert
Oh, Junghwan
Volgin, Andrei
Soghomonyan, Suren
Nishii, Ryuichi
Alauddin, Mian
Mukhopadhay, Uday
Peng, Zhenghong
Bornmann, William
Gelovani, Juri
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) : 947 - 958
[29] Targeting HIF-1 for cancer therapy
Gregg L. Semenza
Nature Reviews Cancer, 2003, 3 : 721 - 732
[30] Targeting HIF-1 for cancer therapy
Semenza, GL
NATURE REVIEWS CANCER, 2003, 3 (10) : 721 - 732

← 1 2 3 4 5 →